title: [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
abstract: We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide). A 78-year-old woman, who presented with left breast cancer, underwent pectoralis-preserving mastectomy when she was 76 years old. Pathological findings were as follows: invasive ductal carcinoma (scirrhous type), pT1c (2.0 cm), n (1/10), ly3, v1, ER (-), PgR (-), HER2: score 1. After one year and a half, a left supraclavicular lymph node metastasis, a left interpectoral lymph node metastasis, and mediastinal lymph nodes metastasis were noted. Capecitabine and cyclophosphamide were administered as first-line chemotherapy. After 8 cycles, all metastases responded, and this therapy is now being continued (19 cycles) on an outpatient basis. The complete response has continued for nine months. XC therapy can be the first-line chemotherapy for elderly metastatic breast cancer patients since it has been effective and no serious side effects have been encountered while maintaining quality of life.
authors.affiliation: Dept. of Surgery, Nippon Medical School.
authors.forename: Shinya
authors.initials: S
authors.lastname: Iida
authors.forename: Kiyonori
authors.initials: K
authors.lastname: Furukawa
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Keiko
authors.initials: K
authors.lastname: Yanagihara
authors.forename: Reiko
authors.initials: R
authors.lastname: Iwasaki
authors.forename: Tomoko
authors.initials: T
authors.lastname: Noguchi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Tsuchiya
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Sugisaki
authors.forename: Zenya
authors.initials: Z
authors.lastname: Naito
authors.forename: Takashi
authors.initials: T
authors.lastname: Tajiri
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008207:Lymphatic Metastasis; D009362:Neoplasm Metastasis; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D003841:Deoxycytidine; D000069287:Capecitabine; D003520:Cyclophosphamide; D005472:Fluorouracil